BAIN CAPITAL INVESTORS LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001040508
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 4 positions · Total reported value $4.48B · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 0.0% · 0 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q1 2024 13F filing, BAIN CAPITAL INVESTORS LLC disclosed 4 equity positions with a combined reported value of $4.48B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.
The largest disclosed positions as of Q1 2024 were CERE ($2.78B), SGRY ($1.49B), AVAH ($203.19M). By sector, the heaviest allocations are Health Care 37.8%, Consumer Discretionary 0.3%. Versus the prior quarter, allocation shifted toward Other (+1.6pp) and away from Health Care (-1.6pp).
Versus the prior quarter, BAIN CAPITAL INVESTORS LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Insider Transactions (Form 4)
Latest BAIN CAPITAL INVESTORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-20 | Buy | Kailera Therapeutics, Inc. | 8,398,438 | $16.00 | SEC filing |
| 2026-04-20 | Conversion | Kailera Therapeutics, Inc. | 17,857,143 | — | SEC filing |
Fund Profile
Bain Capital Investors files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 8 positions worth $4.82B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 8 positions · $4.82B reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: BOBS (BOBS DISC FURNITURE INC) at 31.3%
- Average position size: $601.97M
Sector Tilt
- Health Care 57.3%
- Consumer Discretionary 31.4%
- Information Technology 11.3%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
FAQ
What did BAIN CAPITAL INVESTORS LLC buy in 2024-Q1?
In its 2024-Q1 13F filing, BAIN CAPITAL INVESTORS LLC reported 4 equity positions worth $4.48B in aggregate; its largest disclosed positions were CERE ($2.78B), SGRY ($1.49B), AVAH ($203.19M).
How large is BAIN CAPITAL INVESTORS LLC's portfolio?
BAIN CAPITAL INVESTORS LLC reported $4.48B of long equity holdings across 4 positions as of 2024-Q1. Top-10 holdings account for 100.0% of reported value.
What is BAIN CAPITAL INVESTORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.